Oxurion confirms continuation of discussions regarding its proposed acquisition of a French CRO février 27, 20260CommentsEN NL FR Read More
Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC février 25, 20260CommentsEN NLRead More
Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC février 19, 20260CommentsEN NLRead More
Axiodis CRO accelerates its sales and marketing strategy to support ambitious growth driven by Oxurion février 16, 20260CommentsEN NL FRRead More
Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC janvier 26, 20260CommentsEN NLRead More
Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC janvier 23, 20260CommentsEN NLRead More
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas janvier 19, 20260CommentsEN NLRead More
Oxurion announces the temporary suspension of the financing programme dedicated to investments in digital assets and crypto-assets janvier 19, 20260CommentsEN NL FRRead More
Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC janvier 13, 20260CommentsEN NL Read More
Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC décembre 17, 20250CommentsEN NLRead More
Oxurion secures a binding €30 million financing facility dedicated to investments in digital and crypto-assets décembre 1, 20250CommentsEN NL FR Read More
Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC novembre 25, 20250CommentsEN NLRead More
Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC novembre 20, 20250CommentsEN NLRead More
Informatiedocument Nieuwe Aandelen – 07 november 2025 novembre 9, 20250CommentsInformatie betreffende de toelating tot notering en handel op de gereglementeerde markt van Euronext Brussel van 1.000.000.000 nieuwe aandelenRead More
New Shares Information Document – 07 November 2025 novembre 9, 20250CommentsInformation regarding the admission to listing and trading on the regulated market of euronext brussels of 1,000,000,00 new sharesRead More
Oxurion ends discussions regarding previously announced preclinical transaction and continues integration of a strategic clinical partner novembre 3, 20250CommentsEN NL FRRead More
Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC octobre 23, 20250CommentsEN NLRead More
Oxurion Receives Amended Transparency Notifications from Atlas Special Opportunities II LLC octobre 17, 20250CommentsEN NLRead More
Oxurion Receives Transparency Notifications from Atlas Special Opportunities II LLC octobre 16, 20250CommentsEN NLRead More
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas octobre 15, 20250CommentsEN NLRead More
